{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:56:45Z","timestamp":1792022205527,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2864-0","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T14:05:03Z","timestamp":1513001103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study"],"prefix":"10.1186","volume":"17","author":[{"given":"Sanjeev","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahajal","family":"Dhooria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"issue":"12","key":"2864_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/cid\/ciw125","volume":"62","author":"A Low","year":"2016","unstructured":"Low A, Gavriilidis G, Larke N, B-Lajoie MR, Drouin O, Stover J, Muhe L, Easterbrook P. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(12):1595\u2013603. doi: 10.1093\/cid\/ciw125 .","journal-title":"Clin Infect Dis"},{"key":"2864_CR2","unstructured":"World Health Organization: Global tuberculosis report 2016. Geneva: WHO; 2016. Available: http:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2016_executive_summary.pdf"},{"key":"2864_CR3","volume-title":"Department of AIDSControl, Ministry of Health & Family Welfare: Annual Report 2015\u201316","author":"National AIDS Control Organisation India","year":"2015","unstructured":"National AIDS Control Organisation India. Department of AIDSControl, Ministry of Health & Family Welfare: Annual Report 2015\u201316. New Delhi: National AIDS control organization; 2015. Available: http:\/\/naco.gov.in\/sites\/default\/files\/Annual%20Report%202015-16_NACO.pdf"},{"issue":"12","key":"2864_CR4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/jama.1992.03490120095035","volume":"268","author":"KM De Cock","year":"1992","unstructured":"De Cock KM, Soro B, Coulibaly I, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA. 1992;268(12):1581\u20137.","journal-title":"JAMA"},{"issue":"9","key":"2864_CR5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivist\u00f6 KT. Pharmacokinetic interactions with Rifampicin. Clin Pharmacokinet. 2003;42(9):819\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"2864_CR6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/505210","volume":"43","author":"W Manosuthi","year":"2006","unstructured":"Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. PlasmaNevirapine levels and 24-week efficacy in HIV-infected patients receiving Nevirapine-based highly active antiretroviral therapy with or without Rifampicin. Clin Infect Dis. 2006;43:253\u20135.","journal-title":"Clin Infect Dis"},{"key":"2864_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","volume":"61","author":"K Cohen","year":"2008","unstructured":"Cohen K, van Cutsem G, Boulle A, et al. Effect of Rifampicin-based antitubercular therapy on Nevirapine plasma concentrations inSouth African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61:389\u201393.","journal-title":"J Antimicrob Chemother"},{"key":"2864_CR8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","volume":"14","author":"K Cohen","year":"2009","unstructured":"Cohen K, Grant A, Dandara C, et al. Effect of Rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>Tpolymorphism on Efavirenz concentrations in adults in SouthAfrica. Antivir Ther. 2009;14:687\u201395.","journal-title":"Antivir Ther"},{"key":"2864_CR9","first-page":"689","volume":"68","author":"TN Gengiah","year":"2012","unstructured":"Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on Efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J ClinPharmacol. 2012;68:689\u201395.","journal-title":"Eur J ClinPharmacol"},{"issue":"1","key":"2864_CR10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1471-2334-13-482","volume":"13","author":"S Sinha","year":"2013","unstructured":"Sinha S, Raghunandan P, Chandrashekhar R, Sharma SK, Kumar S, Dhooria S, et al. Nevirapine versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. BMC Infect Dis. 2013;13(1):482.","journal-title":"BMC Infect Dis"},{"key":"2864_CR11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","volume":"53","author":"S Swaminathan","year":"2011","unstructured":"Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily Nevirapine- or Efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53:716\u201324.","journal-title":"Clin Infect Dis"},{"key":"2864_CR12","unstructured":"Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, Thior I, et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis. 2009;13(3):360\u20136."},{"key":"2864_CR13","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","volume":"48","author":"W Manosuthi","year":"2009","unstructured":"Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse transcriptase inhibitor-based regimens in HIV-infected patients receiving Rifampicin: the N2R study. Clin Infect Dis. 2009;48:1752\u20139.","journal-title":"Clin Infect Dis"},{"key":"2864_CR14","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"A Boulle","year":"2008","unstructured":"Boulle A, van Cutsem G, Cohen K, et al. Outcomes of Nevirapine and Efavirenz-based antiretroviral therapy when coadministered with Rifampicin-based antitubercular therapy. JAMA. 2008;300:530\u20139.","journal-title":"JAMA"},{"key":"2864_CR15","doi-asserted-by":"crossref","first-page":"e1013","DOI":"10.1016\/j.ijid.2010.06.016","volume":"14","author":"W Manosuthi","year":"2010","unstructured":"Manosuthi W, Tantanathip P, Chimsuntorn S, Eampokarap B, Thongyen S, Nilkamhang S, et al. Treatment outcomes of patients co-infected with HIV and tuberculosis who received a Nevirapine-based antiretroviral regimen: a four-year prospective study. Int J Infect Dis. 2010;14:e1013\u20137.","journal-title":"Int J Infect Dis"},{"key":"2864_CR16","unstructured":"Overcoming barriers to access: http:\/\/www.msf.org\/en\/article\/high-prices-hinder-access-newer-hiv-drugs-and-optimal-tests-ensure-treatment-working"},{"key":"2864_CR17","unstructured":"GHO | By country | India - statistics summary (2002 - present) [Internet]. WHO. [cited 2017 Jun 14]. Available from: http:\/\/apps.who.int\/gho\/data\/node.country.country-IND"},{"key":"2864_CR18","unstructured":"National AIDS Control Organisation India, Department of AIDS Control, Ministry of Health & Family Welfare: National AIDS control organization: antiretroviral therapy guidelines for HIV-infected adolescents and adults; New Delhi: NACO; 2013. Available: http:\/\/naco.gov.in\/sites\/default\/files\/Antiretroviral%20Therapy%20Guidelines%20for%20HIV-Infected%20Adults%20and%20Adolescents%20May%202013%281%29_0.pdf"},{"issue":"4","key":"2864_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M Muller","year":"2010","unstructured":"Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy forHIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251\u201361.","journal-title":"Lancet Infect Dis"},{"key":"2864_CR20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/QAD.0b013e3280f7751f","volume":"21","author":"WB Park","year":"2007","unstructured":"Park WB, Choe PG, Jo JH, et al. Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. AIDS. 2007;21:875\u20137.","journal-title":"AIDS"},{"key":"2864_CR21","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/01.aids.0000191232.16111.f9","volume":"19","author":"SD Lawn","year":"2005","unstructured":"Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a south African antiretroviral program. AIDS. 2005;19:2050\u20132.","journal-title":"AIDS"},{"key":"2864_CR22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","volume":"9","author":"W Manosuthi","year":"2008","unstructured":"Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose Efavirenz vs. standard-dose Nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received Rifampicin. HIV Med. 2008;9:294\u20139.","journal-title":"HIV Med"},{"key":"2864_CR23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","volume":"363","author":"F Van Leth","year":"2004","unstructured":"Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, et al. Comparison of first-line antiretroviral therapy with regimens including Nevirapine, Efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study. Lancet. 2004;363:1253\u201363.","journal-title":"Lancet"},{"key":"2864_CR24","doi-asserted-by":"crossref","unstructured":"Varshney E, Tandon M, Saha N, Ali S, Shrivastava V. Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Springerplus. 2012;1(1):34.","DOI":"10.1186\/2193-1801-1-34"},{"issue":"3","key":"2864_CR25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","volume":"53","author":"G Ramachandran","year":"2009","unstructured":"Ramachandran G, Kumar AKH, Rajasekaran S, Kumar P, Ramesh K, Anitha S, et al. CYP2B6 G516T polymorphism but not Rifampin Coadministration influences steady-state pharmacokinetics of Efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother. 2009;53(3):863\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2864_CR26","doi-asserted-by":"publisher","unstructured":"Pasquale De Nardo, Elisa Gentilotti, Boniface Nguhuni, Francesco Vairo et al. Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?, Expert Rev Anti-Infect Ther, 14:1, 19-27, DOI: https:\/\/doi.org\/10.1586\/14787210.2016.1116383 .","DOI":"10.1586\/14787210.2016.1116383"},{"key":"2864_CR27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/318706","volume":"32","author":"WM El-Sadr","year":"2001","unstructured":"El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis. 2001;32:623\u201332.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2864-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T05:14:21Z","timestamp":1660108461000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2864-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2864"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2864-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"761"}}